Kangfang Bio-PD-1 obtained FDA breakthrough therapy qualification, third-line treatment of metastatic nasopharyngeal carcinoma

In September 2020, Kangfang Bio announced that the registered clinical trial of Paimrizumab for the third-line treatment of metastatic nasopharyngeal carcinoma reached the primary endpoint of objective response rate (ORR) assessed by independent imaging.

On March 30, Kangfang Biological announced that the FDA granted Paimrizumab breakthrough therapy qualification for the third-line treatment of metastatic nasopharyngeal carcinoma.

In September 2020, Kangfang Bio announced that the registered clinical trial of Paimrizumab for the third-line treatment of metastatic nasopharyngeal carcinoma reached the primary endpoint of objective response rate (ORR) assessed by independent imaging, after previous multi-line treatment Among the patients with nasopharyngeal cancer, they have shown good clinical efficacy and safety, and will communicate with NMPA before applying for new drugs.

In May 2020, Kangfang Bio-Bio submitted to NMPA a new drug application for the treatment of Paimrizumab for relapsed or refractory classic Hodgkin's lymphoma (r/rcHL) after at least second-line chemotherapy .

Pianprizumab was jointly developed and commercialized by Kangfang Biotechnology and Chia Tai Tianqing.

Nasopharyngeal carcinoma is a malignant tumor that occurs in the mucosal epithelium of the nasopharyngeal area, and mostly occurs in the top and side walls of the nasopharynx.